LOW EXPRESSION OF NIBRIN PREDICTS BETTER PROGNOSIS IN PATIENTS WITH OVARIAN CANCER TREATED WITH TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)

被引：0
|
作者：
Aracil, M. [1 ]
Nieto, A. [1 ]
Tanovic, A. [2 ]
Monk, B. J. [3 ]
Kaye, S. B. [4 ]
Poveda, A. [5 ]
Herzog, T. J. [6 ]
Parekh, T. [7 ]
Badri, N. [2 ]
Galmarini, C. M. [1 ]
机构：
[1] PharmaMar, Dept Res & Dev, Madrid, Spain
[2] PharmaMar, Med Affairs, Madrid, Spain
[3] St Josephs Hosp, Creighton Univ Sch Med, Div Gynecol Oncol, Phoenix, AZ USA
[4] Royal Marsden Hosp, Dept Canc Med, Sutton, Surrey, England
[5] Valencian Inst Oncol, Dept Gynecol Oncol, Valencia, Spain
[6] Columbia Univ Coll Phys & Surg, Div Gynecol Oncol, New York, NY 10032 USA
[7] Janssen LLC, Dept Res & Dev, Raritan, NJ USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 3 study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman, Robert L.
    Monk, Bradley J.
    del Carmen, Marcela G.
    Knoblauch, Roland Elmer
    Parekh, Taal V.
    Dawkins, Fitzroy W.
    Maul, Raymond Scott
    Park, Youn Choi
    Herzog, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
    Jones, Robin Lewis
    Herzog, Thomas J.
    Patel, Shreyaskumar
    von Mehren, Margaret
    Schuetze, Scott
    Van Tine, Brian Andrew
    Coleman, Robert L.
    Triantos, Spyridon
    Hu, Peter
    Shalaby, Waleed
    McGowan, Tracy
    Monk, Bradley J.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Zhen Yuan
    Ying Zhang
    Dongyan Cao
    Keng Shen
    Qingshui Li
    Guonan Zhang
    Xiaohua Wu
    Manhua Cui
    Ying Yue
    Wenjun Cheng
    Li Wang
    Pengpeng Qu
    Guangshi Tao
    Jianqing Hou
    Lixin Sun
    Yuanguang Meng
    Guiling Li
    Changzhong Li
    Huirong Shi
    Yaqing Chen
    Journal of Ovarian Research, 14
  • [34] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [35] Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives
    Sehouli, J.
    Alfaro, V.
    Gonzalez-Martin, A.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 556 - +
  • [36] Experience with trabectedin plus pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge
    Colombo, Nicoletta
    Hardy-Bessard, Anne-Claire
    Ferrandina, Gabriella
    Marth, Christian
    Romero, Ignacio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 : 11 - 19
  • [37] CONSERVATIVE SENSITIVITY ANALYSES OF PROGRESSION-FREE SURVIVAL (PFS) OF TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VS. PLD ALONE IN PATIENTS WITH RELAPSED OVARIAN CANCER: OVA-301 STUDY
    Romero, I.
    Pujade-Lauraine, E.
    Tanovic, A.
    Gomez Garcia, J.
    Poveda, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 324 - 325
  • [38] Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) plus PLD in the ET743-OVA-301 clinical trial
    Poveda, A.
    Kaye, S.
    Herzog, T.
    Ghatage, P.
    Meerpohl, H.
    Ngan, H.
    Emerich, J.
    Tercero, J. C.
    Ricci, D.
    Monk, B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 451 - 452
  • [39] Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin plus pegylated liposomal doxorubicin
    Gonzalez-Martin, Antonio
    du Bois, Andreas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 : 3 - 10
  • [40] Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study
    Pignata, S.
    Scambia, G.
    Mazzei, T.
    Arruti Barbia, M.
    Naglieri, E.
    de Sande, L. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 352 - 352
12345